Protocol and rationale for a randomised, double-blind, placebo-controlled phase 3 trial of admilparant (BMS-986278), an oral lysophosphatidic acid receptor 1 antagonist, in patients with idiopathic pulmonary fibrosis: ALOFT-IPF.

Authors

Toby M Maher, Fernando Martinez, Michael Kreuter, Tamera J Corte, Marlies Wijsenbeek, Takashi Ogura, Takafumi Suda, Zuojun Xu, Aryeh Fischer, Yue Wang, Elizabeth Cerullo, Walid Elsharkawi, Aditya Patel, Vincent Cottin

Published in

BMJ open respiratory research. Volume 13. Issue 1. Oct 09, 2026. Epub Oct 09, 2026.

PMID:
42869508
Bibliographic data and abstract were imported from PubMed on 14 Oct 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.